- Home
- IMNM
IMNM
Immunome Inc.
as of 12-26-2025 3:46pm EST
$21.77
$0.80
-3.54%
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $31.44 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.15 - $25.30 | Next Earning Date: | 11-06-2025 |
| Revenue: | $9,679,000 | Revenue Growth: | -4.44% |
| Revenue Growth (this year): | -18.43% | Revenue Growth (next year): | 11.53% |
AI-Powered IMNM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 70.20%
70.20%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immunome Inc. (IMNM)
Barchas Isaac
Sell
Director
IMNM Dec 22, 2025
Avg Cost/Share
$22.03
Shares
383,200
Total Value
$8,330,079.62
Owned After
2,042,432
SIEGALL CLAY B
Buy
President and CEO
IMNM Dec 19, 2025
Avg Cost/Share
$20.48
Shares
7,278
Total Value
$149,053.44
Owned After
860,525
SEC Form 4
Tsai Philip
Buy
Chief Technical Officer
IMNM Dec 19, 2025
Avg Cost/Share
$20.49
Shares
10,000
Total Value
$204,900.00
Owned After
43,300
SEC Form 4
SIEGALL CLAY B
Buy
President and CEO
IMNM Dec 18, 2025
Avg Cost/Share
$21.50
Shares
46,511
Total Value
$999,986.50
Owned After
860,525
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Barchas Isaac | IMNM | Director | Dec 22, 2025 | Sell | $22.03 | 383,200 | $8,330,079.62 | 2,042,432 | |
| SIEGALL CLAY B | IMNM | President and CEO | Dec 19, 2025 | Buy | $20.48 | 7,278 | $149,053.44 | 860,525 | |
| Tsai Philip | IMNM | Chief Technical Officer | Dec 19, 2025 | Buy | $20.49 | 10,000 | $204,900.00 | 43,300 | |
| SIEGALL CLAY B | IMNM | President and CEO | Dec 18, 2025 | Buy | $21.50 | 46,511 | $999,986.50 | 860,525 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Compare IMNM vs Leading Stocks
See how IMNM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.